FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Maurice Petitou

Research Profile

Chemicals & Drugs

Genes & Molecular Sequences

Carbohydrate Sequence

Concepts & Ideas

Phenomena

Living Beings

Rabbits
Rats

Co-author Network

Publications

TOP 3
Fabio Di Giacomo; Serge Fichelson; Daniel Lewandowski; Vanessa Nancy-Portebois; Maurice Petitou; Eric Cabannes; Paul-Henri Romeo
Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells.
Steven T Olson; Richard Swanson; Maurice Petitou
Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.
Nicolas Sapay; Maurice Petitou; Eric Cabannes; Anne Imberty
Molecular model of human heparanase with proposed binding mode of a heparan sulfate oligosaccharide and catalytic amino acids.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Maurice Petitou (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Fabio Di Giacomo; Serge Fichelson; Daniel Lewandowski; Vanessa Nancy-Portebois; Maurice Petitou; Eric Cabannes; Paul-Henri Romeo
Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells.
Haematologica 2012;97(4):491-9.
2012: Steven T Olson; Richard Swanson; Maurice Petitou
Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.
Blood 2012;119(10):2187-95.
2012: Nicolas Sapay; Maurice Petitou; Eric Cabannes; Anne Imberty
Molecular model of human heparanase with proposed binding mode of a heparan sulfate oligosaccharide and catalytic amino acids.
Biopolymers 2012;97(1):21-34.
2011: Nicolas Sapay; Maurice Petitou; Eric Cabannes; Anne Imberty
Molecular modeling of the interaction between heparan sulfate and cellular growth factors: bringing pieces together.
Glycobiology 2011;21(9):1181-93.
2011: Béatrice Hechler; Cécile Leguay; Maurice Petitou; Sébastien Gaertner; Ghina Alame; Jean-Pierre Cazenave; Monique Freund; Christian Gachet
The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.
The Journal of pharmacology and experimental therapeutics 2011;338(2):412-20.
2011: Ahmed El Hadri; Maurice Petitou
Rational design of anticoagulant drugs using oligosaccharide chemistry.
Chimia 2011;65(1-2):14-7.
2010: Thierry Huet; Olivier Kerbarh; Dominique Schols; Pascal Clayette; Cécile Gauchet; Guy Dubreucq; Loïc Vincent; Heidi Bompais; Romain Mazinghien; Olivier Querolle; Arnaud Salvador; Jérôme Lemoine; Bruno Lucidi; Jan Balzarini; Maurice Petitou
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
Antimicrobial agents and chemotherapy 2010;54(1):134-42.
2009: Maurice Petitou; Vanessa Nancy-Portebois; Guy Dubreucq; Vincent Motte; Dick Meuleman; Martin de Kort; Constant van Boeckel; Gerard M T Vogel; Jeffry A J Wisse
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
Thrombosis and haemostasis 2009;102(5):804-10.
2005: Pierre Savi; Beng H Chong; Andreas Greinacher; Yves Gruel; John G Kelton; Theodore E Warkentin; Petra Eichler; Dirk G Meuleman; Maurice Petitou; Jean-Pascal Herault; Roger Cariou; Jean-Marc Herbert
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.
Blood 2005;105(1):139-44.
2004: Steven T Olson; Richard Swanson; Elke Raub-Segall; Tina Bedsted; Morvardi Sadri; Maurice Petitou; Jean-Pascal Hérault; Jean-Marc Herbert; Ingemar Björk
Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
Thrombosis and haemostasis 2004;92(5):929-39.
2004: Alexey Dementiev; Maurice Petitou; Jean-Marc Herbert; Peter G W Gettins
The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity.
Nature structural & molecular biology 2004;11(9):863-7.
2004: Maurice Petitou; Constant van Boeckel
A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
Angewandte Chemie (International ed. in English) 2004;43(24):3118-33.
2003: Mieke Dewerchin; Jean-Pascal Hérault; Goedele Wallays; Maurice Petitou; Paul Schaeffer; Laurence Millet; Jeffrey I Weitz; Lieve Moons; Désiré Collen; Peter Carmeliet; Jean-Marc Herbert
Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin.
Circulation research 2003;93(11):1120-6.
2003: Pierre Savi; AM Pflieger; Jean-Pascal Hérault; charles michaux; Philippe Duchaussoy; Maurice Petitou; Jean-Marc Herbert
Comparative effects of two synthetic oligosaccharides on platelet activation induced by plasma from HIT patients.
Journal of thrombosis and haemostasis : JTH 2003;1(9):2008-13.
2003: Maurice Petitou
[From heparin to synthetic antithrombotic oligosaccharides].
Bulletin de l'Académie nationale de médecine 2003;187(1):47-56; discussion 56-7.
2003: Eugen Sisu; Sasmita Tripathy; Jean-Maurice Mallet; Pierre-A Driguez; Jean-Pascal Hérault; Philippe Sizun; Jean-Marc Herbert; Maurice Petitou; Pierre Sinay
Synthesis of new conformationally constrained pentasaccharides as molecular probes to investigate the biological activity of heparin.
Biochimie 2003;85(1-2):91-9.
2003: Maurice Petitou; Benito Casu; Ulf Lindahl
1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site.
Biochimie 2003;85(1-2):83-9.
2002: Jean-Pascal Hérault; C Gaich; Françoise Bono; Pierre-A Driguez; Philippe Duchaussoy; Maurice Petitou; Jean-Marc Herbert
The structure of synthetic oligosaccharides in relation to factor IXa inhibition.
Thrombosis and haemostasis 2002;88(3):432-5.
2002: Maurice Petitou; Philippe Duchaussoy; Jean-Marc Herbert; Gérald Duc; Mohamed El Hajji; Jean-François Branellec; François Donat; José Necciari; Roger Cariou; Jean Bouthier; Eric Garrigou
The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
Seminars in thrombosis and hemostasis 2002;28(4):393-402.
2002: Jean-Pascal Hérault; André Bernat; F Roye; charles michaux; Paul Schaeffer; Françoise Bono; Maurice Petitou; Jean-Marc Herbert
Pharmacokinetics of new synthetic heparin mimetics.
Thrombosis and haemostasis 2002;87(6):985-9.
2002: Michel A B A Dennissen; Guido J Jenniskens; Martijn Pieffers; Elly M M Versteeg; Maurice Petitou; Jacques H Veerkamp; Toin H van Kuppevelt
Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies.
The Journal of biological chemistry 2002;277(13):10982-6.
2002: Kenneth A Bauer; David W Hawkins; Paul C Peters; Maurice Petitou; Jean-Marc Herbert; Constant van Boeckel; Dirk G Meuleman
Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
Cardiovascular drug reviews 2002;20(1):37-52.
2001: S K Das; Jean-Maurice Mallet; Jacques Esnault; Pierre-A Driguez; Philippe Duchaussoy; Philippe Sizun; Jean-Pascal Herault; Jean-Marc Herbert; Maurice Petitou; Pierre Sinaÿ
Synthesis of conformationally locked L-iduronic acid derivatives: direct evidence for a critical role of the skew-boat 2S0 conformer in the activation of antithrombin by heparin.
Chemistry (Weinheim an der Bergstrasse, Germany) 2001;7(22):4821-34.
2001: Milos Hricovíni; marco Guerrini; Antonella Bisio; Giangiacomo Torri; Maurice Petitou; Benito Casu
Conformation of heparin pentasaccharide bound to antithrombin III.
The Biochemical journal 2001;359(Pt 2):265-72.
2001: Jean-Marc Herbert; Jean-Pascal Hérault; André Bernat; Pierre Savi; Paul Schaeffer; Pierre-A Driguez; Philippe Duchaussoy; Maurice Petitou
SR123781A, a synthetic heparin mimetic.
Thrombosis and haemostasis 2001;85(5):852-60.
2001: Maurice Petitou; Anne Imberty; Philippe Duchaussoy; Pierre-A Driguez; M L Ceccato; F Gourvenec; Philippe Sizun; Jean-Pascal Hérault; S Pérez; Jean-Marc Herbert
Experimental proof for the structure of a thrombin-inhibiting heparin molecule.
Chemistry (Weinheim an der Bergstrasse, Germany) 2001;7(4):858-73.
1999: C Tabeur; Jean-Maurice Mallet; Françoise Bono; Jean-Marc Herbert; Maurice Petitou; Pierre Sinaÿ
Oligosaccharides corresponding to the regular sequence of heparin: chemical synthesis and interaction with FGF-2.
Bioorganic & medicinal chemistry 1999;7(9):2003-12.
1999: J Kovensky; Philippe Duchaussoy; Françoise Bono; M Salmivirta; Philippe Sizun; Jean-Marc Herbert; Maurice Petitou; Pierre Sinaÿ
A synthetic heparan sulfate pentasaccharide, exclusively containing L-iduronic acid, displays higher affinity for FGF-2 than its D-glucuronic acid-containing isomers.
Bioorganic & medicinal chemistry 1999;7(8):1567-80.
1999: Maurice Petitou; Jean-Pascal Hérault; André Bernat; Pierre-A Driguez; Philippe Duchaussoy; JC Lormeau; Jean-Marc Herbert
[New antithrombotic oligosaccharides].
Annales pharmaceutiques françaises 1999;57(3):232-9.
1999: Philippe Duchaussoy; G Jaurand; Pierre-A Driguez; I Lederman; M L Ceccato; F Gourvenec; JM Strassel; Philippe Sizun; Maurice Petitou; Jean-Marc Herbert
Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition.
Carbohydrate research 1999;317(1-4):85-99.
1999: Philippe Duchaussoy; G Jaurand; Pierre-A Driguez; I Lederman; F Gourvenec; JM Strassel; Philippe Sizun; Maurice Petitou; Jean-Marc Herbert
Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for 'polymerisation'.
Carbohydrate research 1999;317(1-4):63-84.
1999: Maurice Petitou; Pierre-A Driguez; Philippe Duchaussoy; Jean-Pascal Hérault; JC Lormeau; Jean-Marc Herbert
Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics.
Bioorganic & medicinal chemistry letters 1999;9(8):1161-6.
1999: Maurice Petitou; Philippe Duchaussoy; Pierre-A Driguez; Jean-Pascal Hérault; JC Lormeau; Jean-Marc Herbert
New synthetic heparin mimetics able to inhibit thrombin and factor Xa.
Bioorganic & medicinal chemistry letters 1999;9(8):1155-60.
1999: Maurice Petitou; Jean-Pascal Hérault; André Bernat; Pierre-A Driguez; Philippe Duchaussoy; JC Lormeau; Jean-Marc Herbert
Synthesis of thrombin-inhibiting heparin mimetics without side effects.
Nature 1999;398(6726):417-22.
1998: Umesh R Desai; Maurice Petitou; Ingemar Björk; Steven T Olson
Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites.
Biochemistry 1998;37(37):13033-41.
1998: Maurice Petitou; Jean-Pascal Hérault; JC Lormeau; A Helmboldt; J M Mallet; Pierre Sinaÿ; Jean-Marc Herbert
Introducing a C-interglycosidic bond in a biologically active pentasaccharide hardly affects its biological properties.
Bioorganic & medicinal chemistry 1998;6(9):1509-16.
1998: CM Dreef-Tromp; JE Basten; M A Broekhoven; Theo van Dinther; Maurice Petitou; Constant van Boeckel
Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers.
Bioorganic & medicinal chemistry letters 1998;8(16):2081-6.
1998: P S Lei; Philippe Duchaussoy; Philippe Sizun; Jean-Maurice Mallet; Maurice Petitou; Pierre Sinaÿ
Synthesis of a 3-deoxy-L-iduronic acid containing heparin pentasaccharide to probe the conformation of the antithrombin III binding sequence.
Bioorganic & medicinal chemistry 1998;6(8):1337-46.
1998: Jean-Marc Herbert; Jean-Pascal Hérault; André Bernat; RG van Amsterdam; JC Lormeau; Maurice Petitou; Constant van Boeckel; P Hoffmann; Dirk G Meuleman
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
Blood 1998;91(11):4197-205.
1998: Umesh R Desai; Maurice Petitou; Ingemar Björk; Steven T Olson
Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin.
The Journal of biological chemistry 1998;273(13):7478-87.
1997: A Badorc; M F Bordes; P de Cointet; Pierre Savi; André Bernat; Alain Lalé; Maurice Petitou; Jean-Pierre Maffrand; Jean-Marc Herbert
New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
Journal of medicinal chemistry 1997;40(21):3393-401.
1997: S Cros; Maurice Petitou; Philippe Sizun; S Pérez; Anne Imberty
Combined NMR and molecular modeling study of an iduronic acid-containing trisaccharide related to antithrombotic heparin fragments.
Bioorganic & medicinal chemistry 1997;5(7):1301-9.
1997: Maurice Petitou; Philippe Duchaussoy; G Jaurand; F Gourvenec; I Lederman; JM Strassel; T Bârzu; B Crépon; Jean-Pascal Hérault; JC Lormeau; André Bernat; Jean-Marc Herbert
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
Journal of medicinal chemistry 1997;40(11):1600-7.
1997: P Hoffmann; André Bernat; A Dumas; Maurice Petitou; Jean-Pascal Hérault; Jean-Marc Herbert
The synthetic pentasaccharide SR 90107A/Org 31540 does not release lipase activity into the plasma.
Thrombosis research 1997;86(4):325-32.
1997: Maurice Petitou; T Barzu; Jean-Pascal Herault; Jean-Marc Herbert
A unique trisaccharide sequence in heparin mediates the early step of antithrombin III activation.
Glycobiology 1997;7(3):323-7.
1996: Jean-Marc Herbert; Jean-Pascal Hérault; André Bernat; R G van Amsterdam; G M Vogel; JC Lormeau; Maurice Petitou; Dirk G Meuleman
Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
Circulation research 1996;79(3):590-600.
1996: ZC Han; Sylvia Bellucci; Z X Shen; J P Maffrand; M Pascal; Maurice Petitou; JC Lormeau; Jacques Caen
Glycosaminoglycans enhance megakaryocytopoiesis by modifying the activities of hematopoietic growth regulators.
Journal of cellular physiology 1996;168(1):97-104.
1996: C Tabeur; F Machetto; Jean-Maurice Mallet; Philippe Duchaussoy; Maurice Petitou; Pierre Sinaÿ
L-iduronic acid derivatives as glycosyl donors.
Carbohydrate research 1996;281(2):253-76.
1995: PD Grootenhuis; P Westerduin; Dirk G Meuleman; Maurice Petitou; Constant van Boeckel
Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity.
Nature structural biology 1995;2(9):736-9.
1994: Z X Shen; N Basara; X D Xi; Jacques Caen; J P Maffrand; M Pascal; Maurice Petitou; JC Lormeau; ZC Han
Fraxiparin, a low-molecular-weight heparin, stimulates megakaryocytopoiesis in vitro and in vivo in mice.
British journal of haematology 1994;88(3):608-12.
1994: D Carrie; C Caranobe; Sylvie Saivin; G Houin; Maurice Petitou; JC Lormeau; Constant van Boeckel; Dirk G Meuleman; Bernard Boneu
Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
Blood 1994;84(8):2571-7.
1994: G Jaurand; C Tabeur; Maurice Petitou
Synthesis of the basic disaccharide unit of heparin.
Carbohydrate research 1994;255():295-301.
1993: T Bârzu; M Level; Maurice Petitou; JC Lormeau; J Choay; D Schols; M Baba; R Pauwels; M Witvrouw; E De Clercq
Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect.
Journal of medicinal chemistry 1993;36(23):3546-55.
1993: P Sie; Dominique Dupouy; C Caranobe; Maurice Petitou; Bernard Boneu
Antithrombotic properties of a dermatan sulfate hexadecasaccharide fractionated by affinity for heparin cofactor II.
Blood 1993;81(7):1771-7.
1992: T Bârzu; A Desmoulière; Jean-Marc Herbert; M Level; Jean-Pascal Herault; Maurice Petitou; JC Lormeau; G Gabbiani; M Pascal
O-acylated heparin derivatives with low anticoagulant activity decrease proliferation and increase alpha-smooth muscle actin expression in cultured arterial smooth muscle cells.
European journal of pharmacology 1992;219(2):225-33.
1992: Sylvie Saivin; Frédérique Dol; C Caranobe; Maurice Petitou; JC Lormeau; P Sie; G Houin; Bernard Boneu
Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit.
Thrombosis research 1992;66(5):527-35.
1992: Sylvie Saivin; C Caranobe; Maurice Petitou; JC Lormeau; G Houin; Bernard Boneu
Pharmacodynamic properties of long lasting butyryl heparin derivatives in the rabbit.
Thrombosis and haemostasis 1992;67(5):550-5.
1992: Sylvie Saivin; C Caranobe; Maurice Petitou; P Sie; JC Lormeau; M Level; B Crepon; G Houin; Bernard Boneu
Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulphate in rabbits.
British journal of haematology 1992;80(4):509-13.
1992: Sylvie Saivin; Maurice Petitou; JC Lormeau; Dominique Dupouy; Pierre Sié; C Caranobe; G Houin; Bernard Boneu
Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effects.
Thrombosis and haemostasis 1992;67(3):346-51.
1992: Sylvie Saivin; Maurice Petitou; JC Lormeau; Dominique Dupouy; P Sie; C Caranobe; G Houin; Bernard Boneu
Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effects.
The Journal of laboratory and clinical medicine 1992;119(2):189-96.
1992: Maurice Petitou
Chemical synthesis and hemisynthesis in the field of glycosaminoglycans.
Advances in experimental medicine and biology 1992;313():21-30.
1990: V Bossennec; Maurice Petitou; B Perly
1H-n.m.r. investigation of naturally occurring and chemically oversulphated dermatan sulphates. Identification of minor monosaccharide residues.
The Biochemical journal 1990;267(3):625-30.
1990: M Ragazzi; D R Ferro; B Perly; Pierre Sinaÿ; Maurice Petitou; J Choay
Conformation of the pentasaccharide corresponding to the binding site of heparin for antithrombin III.
Carbohydrate research 1990;195(2):169-85.
1990: D R Ferro; A Provasoli; M Ragazzi; Benito Casu; Giangiacomo Torri; V Bossennec; B Perly; Pierre Sinaÿ; Maurice Petitou; J Choay
Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences.
Carbohydrate research 1990;195(2):157-67.
1990: Frédérique Dol; Maurice Petitou; JC Lormeau; J Choay; C Caranobe; P Sie; Sylvie Saivin; G Houin; Bernard Boneu
Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
The Journal of laboratory and clinical medicine 1990;115(1):43-51.
1989: A Marra; X Dong; Maurice Petitou; P Sinay
Synthesis of disaccharide fragments of dermatan sulfate.
Carbohydrate research 1989;195(1):39-50.
1989: T Bârzu; JC Lormeau; Maurice Petitou; S Michelson; J Choay
Heparin-derived oligosaccharides: affinity for acidic fibroblast growth factor and effect on its growth-promoting activity for human endothelial cells.
Journal of cellular physiology 1989;140(3):538-48.
1989: Frédérique Dol; Maurice Petitou; J Choay; P Sie; G Houin; Bernard Boneu
Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
Folia haematologica (Leipzig, Germany : 1928) 1989;116(6):851-7.
1988: Frédérique Dol; C Caranobe; Dominique Dupouy; Maurice Petitou; JC Lormeau; J Choay; Pierre Sié; Bernard Boneu
Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties.
Thrombosis research 1988;52(2):153-64.
1988: Maurice Petitou; J C Lormeau; J Choay
Interaction of heparin and antithrombin III. The role of O-sulfate groups.
European journal of biochemistry / FEBS 1988;176(3):637-40.
1988: Maurice Petitou; Philippe Duchaussoy; I Lederman; J Choay; Pierre Sinaÿ
Binding of heparin to antithrombin III: a chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-D-glucose residue.
Carbohydrate research 1988;179():163-72.
1988: Pierre Sié; Maurice Petitou; JC Lormeau; Dominique Dupouy; Bernard Boneu; J Choay
Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II.
Biochimica et biophysica acta 1988;966(2):188-95.
1988: Maurice Petitou; J C Lormeau; B Perly; P Berthault; V Bossennec; P Sié; J Choay
Is there a unique sequence in heparin for interaction with heparin cofactor II? Structural and biological studies of heparin-derived oligosaccharides.
The Journal of biological chemistry 1988;263(18):8685-90.
1988: Yves Cadroy; Frédérique Dol; C Caranobe; Maurice Petitou; JC Lormeau; Pierre Sié; J Choay; Bernard Boneu
Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
Thrombosis and haemostasis 1988;59(2):295-8.
1987: Maurice Petitou; Philippe Duchaussoy; I Lederman; J Choay; Jean-Claude Jacquinet; Pierre Sinaÿ; Giangiacomo Torri
Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III.
Carbohydrate research 1987;167():67-75.
1987: T Barzu; J L van Rijn; Maurice Petitou; Gérard Tobelem; Jacques Caen
Heparin degradation in the endothelial cells.
Thrombosis research 1987;47(5):601-9.
1987: M Ragazzi; D R Ferro; B Perly; Giangiacomo Torri; Benito Casu; Pierre Sinaÿ; Maurice Petitou; J Choay
Conformation of the pentasaccharide corresponding to the binding site of heparin to antithrombin-III.
Carbohydrate research 1987;165(1):c1-5.
1986: C Caranobe; Maurice Petitou; Dominique Dupouy; A M Gabaig; Pierre Sié; Michael Buchanan; Bernard Boneu
Heparin fractions with high and low affinities to antithrombin III are cleared at different rates.
Thrombosis research 1986;43(6):635-41.
1986: T Bârzu; J L Van Rijn; Maurice Petitou; P Molho; G Tobelem; J P Caen
Endothelial binding sites for heparin. Specificity and role in heparin neutralization.
The Biochemical journal 1986;238(3):847-54.
1986: Benito Casu; J Choay; D R Ferro; G Gatti; Jean-Claude Jacquinet; Maurice Petitou; A Provasoli; M Ragazzi; P Sinay; Giangiacomo Torri
Controversial glycosaminoglycan conformations.
Nature 1986;322(6076):215-6.
1986: Maurice Petitou; Philippe Duchaussoy; I Lederman; J Choay; Pierre Sinaÿ; Jean-Claude Jacquinet; Giangiacomo Torri
Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-D-glucopyranosyl)-(1-4 )-O-(beta-D-glucopyranosyluronic acid)-(1-4)-O-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-alpha-D-glu copyranosyl)-(1-4)-O-(2-O-sulfo-alpha-L-idopyranosyluronic acid)-(1-4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III.
Carbohydrate research 1986;147(2):221-36.
1985: T Bârzu; P Molho; G Tobelem; Maurice Petitou; J Caen
Binding and endocytosis of heparin by human endothelial cells in culture.
Biochimica et biophysica acta 1985;845(2):196-203.
1985: Giangiacomo Torri; Benito Casu; G Gatti; Maurice Petitou; J Choay; Jean-Claude Jacquinet; Pierre Sinaÿ
Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue.
Biochemical and biophysical research communications 1985;128(1):134-40.
1984: T Bârzu; P Molho; G Tobelem; Maurice Petitou; J P Caen
Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture.
Nouvelle revue française d'hématologie 1984;26(4):243-7.
1981: Benito Casu; Pasqua Oreste; Giangiacomo Torri; Giorgio Zoppetti; J Choay; JC Lormeau; Maurice Petitou; P Sinäy
The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies.
The Biochemical journal 1981;197(3):599-609.
1980: J Choay; JC Lormeau; Maurice Petitou; P Sinay; Benito Casu; Pasqua Oreste; Giangiacomo Torri; G Gatti
Anti-Xa active heparin oligosaccharides.
Thrombosis research 1980;18(3-4):573-8.